Key considerations in the preclinical development of biosimilars

Area of Science:

• Biopharmaceutical development
• Regulatory science
• Drug evaluation

Background:

• Biosimilar development necessitates careful selection of a reference biologic.
• Understanding and replicating key molecular attributes of the reference biologic is crucial.
• Manufacturing processes must be developed to match the reference biologic product.

Purpose of the Study:

• To clarify the preclinical development and evaluation process for biosimilars.
• To explain the requirements set forth by regulatory agencies like the European Medicines Agency (EMA) and the Food and Drug Administration (FDA).
• To provide a foundation for understanding the steps preceding clinical testing in humans.

Main Methods:

• Review of European Medicines Agency (EMA) and FDA guidance documents on biosimilar development.
• Analysis of the essential components of biosimilar preclinical evaluation.
• Focus on the similarity assessment framework mandated by regulatory bodies.

Main Results:

• Biosimilars require a rigorous similarity evaluation instead of extensive novel biologic studies.
• Preclinical development focuses on matching critical molecular attributes and manufacturing processes.
• Regulatory guidelines emphasize a stepwise approach to biosimilar approval.

Conclusions:

• Understanding the preclinical evaluation is key to successful biosimilar development.
• Regulatory requirements ensure biosimilars meet stringent similarity standards.
• This process streamlines the pathway to clinical trials for biosimilar candidates.